Last $38.06 USD
Change Today +0.46 / 1.22%
Volume 354.8K
MYGN On Other Exchanges
As of 8:10 PM 07/11/14 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

John Tannahill Henderson BSc. M.B, Ch.B, MRCP, M.D., Ph.D.

Chairman, Chairman of Strategic Committee, Member of Nominating & Governance Committee and Member of Compensation Committee, Myriad Genetics Inc.
AgeTotal Calculated CompensationThis person is connected to 50 board members in 4 different organizations across 6 different industries.

See Board Relationships


Dr. John Tannahill Henderson, BSc. M.B, Ch.B, MRCP, M.D. serves as the President of FuturePharm LLC. Dr. Henderson has been a Consultant to the Pharmaceutical industry through Futurepharm LLC since December 2000. He has extensive experience in a broad range of therapeutic areas, including cardiovascular, the central nervous system, anti-infective, anti-inflammatory agents, urology and gastro-enterology. Prior to FuturePharm LLC, from December 1974 to December 2000, he ...

Read Full Background

Corporate Headquarters*

320 Wakara Way
Salt Lake City, Utah 84108

United States

Phone: 801-584-3600
Fax: 801-584-3640

Board Members Memberships*

Former Lead Director, Member of Audit Committee and Member of Corporate Governance and Nominating Committee
Chairman, Chairman of Strategic Committee, Member of Nominating & Governance Committee and Member of Compensation Committee
Former Director
Director, Member of Nominating & Governance Committee and Member of Audit Committee
Former Director, Chairman of Nominating & Governance Committee and Member of Audit Committee


Bachelor's Degree 1965
University of Edinburgh in Scotland
MD 1968
University of Edinburgh in Scotland

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

Exercisable Options210,000
Unexercisable Options30,000
Total Number of Options240,000

Total Compensation*

Total Annual Cash Compensation$180,000
Total Calculated Compensation$484,854
*Data is at least as current as the most recent Definitive Proxy.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $38.06 USD +0.46


Peer M. Schatz Chairman of Management Board, Chief Executive Officer and Managing Director
Qiagen NV
Marc D. Grodman M.D.Founder, Chairman, Chief Executive Officer, President and Managing Director
Bio-Reference Laboratories Inc.
Russell Cummings Chief Executive Officer, Executive Director, and Member of Investment Committee
Imperial Innovations Group plc
210.0K GBP
Kimberly J. Popovits Chairman of the Board, Chief Executive Officer, President and Member of Non-Management Stock Option Committee
Genomic Health Inc.
Michael J. Pellini M.D., MBAChief Executive Officer, President and Director
Foundation Medicine, Inc.
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at